InnoCare Pharma Statistics

Total Valuation

InnoCare Pharma has a market cap or net worth of HKD 18.88 billion. The enterprise value is 12.77 billion.

Market Cap	18.88B
Enterprise Value	12.77B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has increased by 0.57% in one year.

Current Share Class	n/a
Shares Outstanding	1.76B
Shares Change (YoY)	+0.57%
Shares Change (QoQ)	+26.66%
Owned by Insiders (%)	21.37%
Owned by Institutions (%)	35.92%
Float	1.30B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.04
PB Ratio	2.34
P/TBV Ratio	2.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-30.71
EV / Sales	12.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.42

Financial Position

The company has a current ratio of 7.74, with a Debt / Equity ratio of 0.23.

Current Ratio	7.74
Quick Ratio	7.27
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	-2.20
Interest Coverage	-24.89

Financial Efficiency

Return on equity (ROE) is -5.52% and return on invested capital (ROIC) is -4.88%.

Return on Equity (ROE)	-5.52%
Return on Assets (ROA)	-4.03%
Return on Invested Capital (ROIC)	-4.88%
Return on Capital Employed (ROCE)	-7.45%
Revenue Per Employee	914,299
Profits Per Employee	-381,930
Employee Count	1,089
Asset Turnover	0.09
Inventory Turnover	1.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +80.12% in the last 52 weeks. The beta is 1.03, so InnoCare Pharma's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+80.12%
50-Day Moving Average	6.22
200-Day Moving Average	5.68
Relative Strength Index (RSI)	79.35
Average Volume (20 Days)	14,144,067

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCare Pharma had revenue of HKD 995.67 million and -415.92 million in losses. Loss per share was -0.24.

Revenue	995.67M
Gross Profit	856.57M
Operating Income	-696.34M
Pretax Income	-432.20M
Net Income	-415.92M
EBITDA	-615.91M
EBIT	-696.34M
Loss Per Share	-0.24

Full Income Statement

Balance Sheet

The company has 7.85 billion in cash and 1.71 billion in debt, giving a net cash position of 6.13 billion or 3.48 per share.

Cash & Cash Equivalents	7.85B
Total Debt	1.71B
Net Cash	6.13B
Net Cash Per Share	3.48
Equity (Book Value)	7.56B
Book Value Per Share	3.98
Working Capital	7.59B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -611.94 million and capital expenditures -165.91 million, giving a free cash flow of -777.85 million.

Operating Cash Flow	-611.94M
Capital Expenditures	-165.91M
Free Cash Flow	-777.85M
FCF Per Share	-0.44

Full Cash Flow Statement

Margins

Gross margin is 86.03%, with operating and profit margins of -69.94% and -41.77%.

Gross Margin	86.03%
Operating Margin	-69.94%
Pretax Margin	-43.41%
Profit Margin	-41.77%
EBITDA Margin	-61.86%
EBIT Margin	-69.94%
FCF Margin	n/a

Dividends & Yields

InnoCare Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.57%
Shareholder Yield	-0.57%
Earnings Yield	-2.20%
FCF Yield	-4.12%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCare Pharma has an Altman Z-Score of 2.21. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.21
Piotroski F-Score	n/a